Organon & Co. (OGN)
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - General
Organon & Co.
NYSE:OGNHealthcare · Drug Manufacturers - General
+0.00%$13.75
AH Close$13.75+0.00%vs close
AH Close$13.75+0.00%vs close
Mkt Cap$3.61B
Float261.48M
O/S262.61M
Inst Own83.1%
SI7.3%
Div Yield0.58%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$6.22B
Net Income$187M
Total Assets$12.87B
Free Cash Flow$538M
Debt & Equity
Debt 92%
Equity 8%
Total Debt$8.8B
Total Equity$752M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in OGN's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$12.87B
Liabilities$12.12B
Accounts Receivable$1.43B
Accounts Payable$952M
Inventory$1.41B
PP&E (Net)$1.3B
Goodwill$4.15B
Intangible Assets$1.13B
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $6.22B | $6.4B | $6.26B | $6.17B | $6.3B | $6.53B | $7.78B | $9.78B | $10.5B |
| YoY Growth | -2.9% | 2.2% | 1.4% | -2.1% | -3.5% | -16.0% | -20.5% | -6.9% | - |
| Cost of Revenue | $2.85B | $2.69B | $2.52B | $2.29B | $2.38B | $2.12B | $2.27B | $4.69B | $4.59B |
| Gross Profit | $3.36B | $3.71B | $3.75B | $3.88B | $3.92B | $4.41B | $5.5B | $5.08B | $5.91B |
| Gross Margin | 54.1% | 58.0% | 59.8% | 62.8% | 62.2% | 67.6% | 70.8% | 52.0% | 56.3% |
| Research and Development | $366M | $469M | $528M | $471M | $443M | $210M | $220M | $365M | $355M |
| Selling, General, and Administrative | $1.71B | $1.76B | $1.89B | $1.7B | $1.67B | $1.36B | $1.44B | $2.01B | $2.29B |
| Other | $10M | $0 | $0 | $0 | -$104M | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $2.09B | $2.23B | $2.42B | $2.17B | $2.01B | $1.57B | $1.66B | $2.38B | $2.64B |
| Operating Income (EBIT) | $1.28B | $1.49B | $1.33B | $1.71B | $1.92B | $2.85B | $3.85B | $2.71B | $3.27B |
| Operating Margin | 20.7% | 23.2% | 21.2% | 27.6% | 30.4% | 43.6% | 49.5% | 27.7% | 31.2% |
| Interest Expense | $504M | $520M | $527M | $422M | $258M | $6M | $6M | $0 | $0 |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $0 | $19M | $0 | $11M |
| Other Income (Expense) | -$860M | -$679M | -$654M | -$583M | -$386M | -$95M | -$144M | $23M | -$173M |
| Income Before Tax (EBT) | $425M | $807M | $673M | $1.12B | $1.53B | $2.75B | $3.7B | $2.73B | $3.1B |
| Income Tax Expense | $238M | -$57M | -$350M | $205M | $178M | $496M | $390M | $576M | $1.3B |
| Net Income | $187M | $864M | $1.02B | $917M | $1.35B | $2.16B | $3.22B | $2.15B | $1.8B |
| Net Income Margin | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% | 33.1% | 41.4% | 22.0% | 17.2% |
| Supplementary Data | |||||||||
| EPS | 0.72 | 3.36 | 4.01 | 3.61 | 5.33 | 8.52 | 12.71 | 8.51 | 7.11 |
| Diluted EPS | 0.72 | 3.33 | 3.99 | 3.59 | 5.33 | 8.52 | 12.71 | 8.51 | 7.11 |
| Weighted Average OS | 259.50M | 257.05M | 255.24M | 254.08M | 253.55M | 253.52M | 253.13M | 253.13M | 253.13M |
| EBITDA | $1.29B | $1.6B | $1.44B | $1.76B | $1.98B | $2.99B | $3.89B | $4.38B | $5.08B |
| EBITDA Margin | 20.8% | 25.1% | 22.9% | 28.4% | 31.4% | 45.8% | 50.1% | 44.8% | 48.4% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $574M | $675M | $693M | $706M | $737M | $12M | $319M | $244M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $574M | $675M | $693M | $706M | $737M | $12M | $319M | $244M |
| Accounts Receivable | $1.43B | $1.49B | $1.86B | $1.61B | $1.51B | $1.41B | $1.57B | $1.59B |
| Inventory | $1.41B | $1.32B | $1.31B | $1B | $915M | $913M | $1.07B | $994M |
| Other Current Assets | $939M | $861M | $643M | $616M | $596M | $1.24B | $992M | $883M |
| Total Current Assets | $4.35B | $4.35B | $4.51B | $3.93B | $3.76B | $3.57B | $3.96B | $3.71B |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $1.3B | $1.32B | $1.36B | $1.23B | $1.2B | $1.01B | $762M | $651M |
| Goodwill | $4.15B | $4.68B | $4.6B | $4.6B | $4.6B | $4.6B | $4.6B | $4.6B |
| Intangible Assets | $1.13B | $1.41B | $533M | $649M | $651M | $503M | $569M | $812M |
| Long-Term Investments | $0 | $27M | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $946M | $808M | $267M | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.93B | $361M | $250M | $272M | $464M | $421M | $659M | $714M |
| Total Long-Term Assets | $8.52B | $8.75B | $7.55B | $7.02B | $6.92B | $6.54B | $6.59B | $6.78B |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $12.87B | $13.1B | $12.06B | $10.96B | $10.68B | $10.11B | $10.55B | $10.49B |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $952M | $1.15B | $1.31B | $1.13B | $1.38B | $259M | $258M | $289M |
| Short-Term Debt | $56M | $64M | $55M | $57M | $55M | $8M | $48M | $115M |
| Current Income Tax Payable | $0 | $134M | $206M | $184M | $185M | $288M | $242M | $322M |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $322M |
| Other Current Liabilities | $1.3B | $1.37B | $1.34B | $1.14B | $975M | $2.12B | $793M | $6M |
| Total Current Liabilities | $2.39B | $2.72B | $2.92B | $2.51B | $2.6B | $2.67B | $1.34B | $1.54B |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $8.64B | $8.86B | $8.75B | $8.9B | $9.13B | $0 | $70M | $34M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $57M | $74M | $47M | $19M | $4M | $128M | $139M | $149M |
| Other Long-Term Liabilities | $924M | $865M | $287M | $261M | $279M | $1.8B | $1.9B | $2.57B |
| Total Long-Term Liabilities | $9.72B | $9.91B | $9.21B | $9.34B | $9.59B | $1.95B | $2.17B | $2.6B |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $12.12B | $12.63B | $12.13B | $11.85B | $12.19B | $4.62B | $3.51B | $4.15B |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $6.11B | $7.95B | $7.26B |
| Retained Earnings | $1.11B | $1.01B | $443M | -$331M | -$998M | $0 | $0 | $0 |
| Comprehensive Income & Other | -$527M | -$649M | -$541M | -$564M | -$513M | -$622M | -$914M | -$908M |
| Other Stockholders' Equity | -$360M | -$541M | -$516M | -$564M | -$513M | -$622M | -$914M | -$908M |
| Total Equity | $752M | $472M | -$70M | -$892M | -$1.51B | $5.49B | $7.04B | $6.35B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $12.87B | $13.1B | $12.06B | $10.96B | $10.68B | $10.11B | $10.55B | $10.49B |
| Supplementary Data | ||||||||
| Total Debt | $8.8B | $9.04B | $8.93B | $9.11B | $9.36B | $31M | $186M | $149M |
| Net Debt | $8.23B | $8.36B | $8.24B | $8.41B | $8.63B | $19M | -$133M | -$95M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | $187M | $864M | $1.02B | $917M | $1.35B | $2.26B | $3.31B | $2.15B | $1.8B |
| Depreciation & Amortization | $361M | $277M | $236M | $212M | $195M | $142M | $333M | $1.67B | $1.97B |
| Deferred Income Tax | $63M | -$160M | -$485M | -$18M | -$288M | -$32M | $12M | $37M | -$1.04B |
| Stock-Based Compensation | $77M | $105M | $101M | $75M | $59M | $40M | $41M | $56M | $56M |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | $79M | $383M | -$212M | -$123M | -$277M | $159M | $200M | $250M | $533M |
| Inventory | -$13M | -$131M | -$230M | -$220M | -$138M | -$29M | -$91M | $44M | $72M |
| Accounts Payable | -$217M | -$157M | $163M | -$237M | $663M | $27M | -$35M | $20M | -$14M |
| Other Working Capital | -$96M | -$373M | $124M | $128M | $454M | -$354M | -$746M | -$488M | -$2.03B |
| Total Working Capital Change | -$247M | -$278M | -$155M | -$452M | $702M | -$197M | -$672M | -$174M | -$1.44B |
| Other Non-Cash Items | $259M | $131M | $79M | $124M | $439M | -$22M | -$253M | -$58M | $5.48B |
| Net Cash from Operating | $700M | $939M | $799M | $858M | $2.46B | $2.19B | $2.77B | $3.69B | $3.42B |
| Investing Activities | |||||||||
| Capital Expenditures | -$192M | -$351M | -$259M | -$427M | -$488M | -$278M | -$92M | -$101M | -$86M |
| Acquisitions | -$198M | -$166M | -$2M | -$124M | -$185M | $5M | $7M | $32M | $30M |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $4M | $1M | $131M | $192M | $15M | -$17M | $32M | $30M |
| Net Cash from Investing | -$390M | -$513M | -$260M | -$420M | -$481M | -$258M | -$102M | -$69M | -$56M |
| Financing Activities | |||||||||
| Debt Repaid | $458M | $11M | $258M | $108M | -$9.36B | - | - | -$18M | $4M |
| Common Stock Issuance | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | -$22M | -$17M | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$88M | -$297M | -$294M | -$290M | -$145M | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$15M | -$38M | $0 | -$35M | -$9.03B | -$3.69B | -$2.62B | -$4.22B | -$3.37B |
| Net Cash from Financing | -$561M | -$368M | -$569M | -$433M | -$1.33B | -$2.17B | -$2.62B | -$4.16B | -$3.37B |
| Forex Effect | $150M | -$76M | $17M | -$36M | $23M | -$3M | $31M | $19M | -$36M |
| Net Change in Cash | -$101M | -$18M | -$13M | -$31M | $667M | -$249M | $75M | -$527M | -$45M |
| Supplementary Data | |||||||||
| Operating Cash Flow | $700M | $939M | $799M | $858M | $2.46B | $2.19B | $2.77B | $3.69B | $3.42B |
| Capital Expenditure | -$162M | -$351M | -$261M | -$427M | -$488M | -$278M | -$92M | -$101M | -$86M |
| Free Cash Flow | $538M | $588M | $538M | $431M | $1.97B | $1.91B | $2.67B | $3.59B | $3.33B |
| Cash at Beginning | $675M | $693M | $706M | $737M | $70M | $319M | $244M | $771M | $816M |
| Cash at End | $574M | $675M | $693M | $706M | $737M | $70M | $319M | $244M | $771M |